AR072227A1 - Derivados de triazinona sustituidos - Google Patents

Derivados de triazinona sustituidos

Info

Publication number
AR072227A1
AR072227A1 ARP090102315A ARP090102315A AR072227A1 AR 072227 A1 AR072227 A1 AR 072227A1 AR P090102315 A ARP090102315 A AR P090102315A AR P090102315 A ARP090102315 A AR P090102315A AR 072227 A1 AR072227 A1 AR 072227A1
Authority
AR
Argentina
Prior art keywords
group
alkyl group
alkyl
optionally substituted
amino
Prior art date
Application number
ARP090102315A
Other languages
English (en)
Inventor
Alistair Lochead
Mourad Saady
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis
Publication of AR072227A1 publication Critical patent/AR072227A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)

Abstract

Uso en tratamiento terapeutico, procesos de obtencion y composiciones farmaceuticas para tratamiento preventivo o terapeutico de enfermedades neurodegenerativas provocadas por actividad anormal de GSK3B Reivindicacion 1: Un derivado de triazinona representado por la formula (1) o una sal del mismo, donde: Z representa un enlace, un grupo carbonilo o un metileno opcionalmente sustituido con uno o dos grupos elegidos entre un grupo alquilo C1-6, un grupo hidroxilo o un grupo alcoxi C1-6; R1 representa un anillo de 4-piridina: R2 representa un  tono de hidrogeno o un alquilo C1-6; R3 representa un  tomo de hidrogeno o un grupo alquilo C1-6; R2 y R3 pueden formar juntos un ciclo de 6 miembros con los nitrogenos que tienen R2 y R3 opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6; R4 representa: un anillo de fenilo, estando este anillo opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6, un  tomo de halogeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo hidroxilo, un grupo alcoxi C1-6, un grupo alcoxi C1-2 perhalogenado, un grupo alquilsulfonilo C1-6, un nitro, un ciano, un amino, un grupo monoalquil C1-6-amino o un grupo dialquil C2-12-amino, un grupo acetoxi o un grupo aminosulfonilo; n representa de 0 a 2; en forma de una base libre o de una sal de adicion con un  cido.
ARP090102315A 2008-06-26 2009-06-24 Derivados de triazinona sustituidos AR072227A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290617A EP2138488A1 (en) 2008-06-26 2008-06-26 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AR072227A1 true AR072227A1 (es) 2010-08-11

Family

ID=39832570

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102315A AR072227A1 (es) 2008-06-26 2009-06-24 Derivados de triazinona sustituidos

Country Status (23)

Country Link
US (1) US8592580B2 (es)
EP (2) EP2138488A1 (es)
JP (1) JP5581318B2 (es)
KR (1) KR20110025219A (es)
CN (1) CN102137854A (es)
AR (1) AR072227A1 (es)
AT (1) ATE538114T1 (es)
AU (1) AU2009263846A1 (es)
BR (1) BRPI0914662A2 (es)
CA (1) CA2729115A1 (es)
CY (1) CY1112642T1 (es)
DK (1) DK2321295T3 (es)
EA (1) EA201170095A1 (es)
ES (1) ES2379220T3 (es)
IL (1) IL210174A0 (es)
MX (1) MX2010014235A (es)
NZ (1) NZ590116A (es)
PL (1) PL2321295T3 (es)
PT (1) PT2321295E (es)
SI (1) SI2321295T1 (es)
TW (1) TW201004935A (es)
WO (1) WO2009156860A2 (es)
ZA (1) ZA201100026B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138498A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138493A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138492A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138485A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014023919A8 (pt) * 2012-03-30 2018-01-16 Nissan Chemical Ind Ltd composto da fórmula (i); inibidores dos canais de cálcio do tipo-t; agente de prevenção, um agente terapêutico, e/ou um agente para melhoria de uma doença tratável pela ação inibitória do canal de cálcio do tipo-t; agente terapêutico para dor neuropática e medicamento
SI2841428T1 (sl) 2012-04-24 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
EP3424920B1 (en) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EP3154953B1 (en) * 2014-06-13 2018-04-04 Fondazione Istituto Italiano di Tecnologia Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) * 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
EG13192A (en) 1976-02-10 1982-12-31 Rhone Poulenc Ind Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent
HU178496B (en) 1977-12-29 1982-05-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity
US4406897A (en) 1981-07-06 1983-09-27 William H. Rorer, Inc. 6-Aryl-4-hydrazinyl-s-triazin-2-ones
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
AU700078B2 (en) 1995-11-01 1998-12-17 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
EP1136484A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Arylalkylamino)pyrimidone derivatives
CA2665516A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
EP1430056B1 (en) 2001-09-21 2005-10-26 Sanofi-Aventis Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
EP1454909B1 (en) 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP1460076A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
ES2330789T3 (es) * 2005-06-30 2009-12-15 Janssen Pharmaceutica Nv Anilino-piridinotriazinas ciclicas como inhibidores de gsk-3.
EP1790649A1 (en) 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
MX2009001913A (es) * 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
WO2008044700A1 (fr) * 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
EP1992624A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
ZA201100026B (en) 2012-04-25
US20110144114A1 (en) 2011-06-16
US8592580B2 (en) 2013-11-26
JP2011525905A (ja) 2011-09-29
BRPI0914662A2 (pt) 2015-10-20
CY1112642T1 (el) 2016-02-10
CN102137854A (zh) 2011-07-27
EA201170095A1 (ru) 2011-08-30
PL2321295T3 (pl) 2012-06-29
SI2321295T1 (sl) 2012-04-30
EP2321295A2 (en) 2011-05-18
JP5581318B2 (ja) 2014-08-27
ES2379220T3 (es) 2012-04-23
WO2009156860A2 (en) 2009-12-30
CA2729115A1 (en) 2009-12-30
MX2010014235A (es) 2011-06-24
NZ590116A (en) 2011-10-28
KR20110025219A (ko) 2011-03-09
EP2138488A1 (en) 2009-12-30
IL210174A0 (en) 2011-03-31
ATE538114T1 (de) 2012-01-15
EP2321295B1 (en) 2011-12-21
DK2321295T3 (da) 2012-04-10
TW201004935A (en) 2010-02-01
WO2009156860A3 (en) 2010-03-04
PT2321295E (pt) 2012-03-23
AU2009263846A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
AR072227A1 (es) Derivados de triazinona sustituidos
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR072224A1 (es) Derivados de pirimidona sustituidos
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
EA202090658A1 (ru) Ингибиторы кэп-зависимой эндонуклеазы
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR067646A1 (es) Ariloxazoles sustituidos y su uso
ECSP11011083A (es) Nuevos compuestos
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR057159A1 (es) N- fenil fenilacetamida, inhibidores inntr
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR043485A1 (es) Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
AR072225A1 (es) Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
AR064424A1 (es) Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio.
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.

Legal Events

Date Code Title Description
FB Suspension of granting procedure